Drugs / HIV-1 gag DNA
HIV-1 gag DNA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00195312 | Aug 2005 → Aug 2007 | HIV infectious disease | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00111605 | ? → May 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00115960 | ? → Jul 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIV-1 gag DNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00111605 ↗ |
| Known as | HIV-1 gag DNA vaccine | “Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12” NCT00111605 ↗ |
| Known as | p37 | “of an RNA-optimized truncated HIV-1 gag gene (p37) DNA derived from strain HXB2 administered either alone or in combination with dose-escalation of IL-12 or IL-15 plasmid...” PMID 22242162 ↗ Jan 2012 |
| Modality | Vaccine | “HIV-1 Gag DNA Vaccine” NCT00195312 ↗ |